Q-omics provides the consensus-scored FAM86DP profile across patient tissues and cancer cell-line models. FAM86DP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAM86DP is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, FAM86DP RNA expression shows 18,160 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, THCA, and ACC as cancer lineages where FAM86DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86DP survival associations across molecular data types. FAM86DP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86DP RNA expression–survival associations across cancer types. High FAM86DP expression shows unfavorable associations in LIHC, ACC, KIRC and MESO, but favorable associations in UVM and OV. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FAM86DP RNA expression.
This table summarizes FAM86DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86DP shows lower tumor expression in BRCA and higher tumor expression in THCA, COAD, LIHC, LUAD and KIRP. The THCA box plot shows higher FAM86DP RNA expression in tumor versus normal tissue (log2 FC = +1.112, t-test p < 0.001).
This table shows molecular features associated with FAM86DP in patient tissues and cancer cell lines. In patient samples, FAM86DP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
